DrugPatentWatch Database Preview

Ivosidenib - Generic Drug Details

« Back to Dashboard

What are the generic sources for ivosidenib and what is the scope of freedom to operate?

Ivosidenib is the generic ingredient in one branded drug marketed by Servier and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ivosidenib has ninety-seven patent family members in thirty-five countries.

Summary for ivosidenib

International Patents:	97
US Patents:	7
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	37
Clinical Trials:	18
Patent Applications:	72
What excipients (inactive ingredients) are in ivosidenib?	ivosidenib excipients list
DailyMed Link:	ivosidenib at DailyMed

Recent Clinical Trials for ivosidenib

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
M.D. Anderson Cancer Center	Phase 1
Washington University School of Medicine	Phase 2
University of Chicago	Phase 1

See all ivosidenib clinical trials

US Patents and Regulatory Information for ivosidenib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Servier	TIBSOVO	ivosidenib	TABLET;ORAL	211192-001	Jul 20, 2018		RX	Yes	Yes
Servier	TIBSOVO	ivosidenib	TABLET;ORAL	211192-001	Jul 20, 2018		RX	Yes	Yes
Servier	TIBSOVO	ivosidenib	TABLET;ORAL	211192-001	Jul 20, 2018		RX	Yes	Yes			Y
Servier	TIBSOVO	ivosidenib	TABLET;ORAL	211192-001	Jul 20, 2018		RX	Yes	Yes

International Patents for ivosidenib

Country	Patent Number	Estimated Expiration
Mexico	2016011810
European Patent Office	2804851
Eurasian Patent Organization	026723
India	5986DEN2014